insights_auto
Why is EBS down 3.36%?
Dive Deeperchevron_right
EBS:NYSE
Emergent Biosolutions Inc
$5.61
arrow_downward
-3.36%(-0.19) 1D
$5.61
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 17, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EBS...
Open
$5.90
High
$5.90
Low
$5.55
Mkt. cap
288.44M
Avg. vol.
1.08M
Volume
872.84K
52-wk high
$14.06
52-wk low
$4.36
EPS
-$5.05
Beta
2.37
Shares outstanding
51.42M
No. of employees
900
Open
$5.90
High
$5.90
Low
$5.55
Mkt. cap
288.44M
Avg. vol.
1.08M
Volume
872.84K
52-wk high
$14.06
52-wk low
$4.36
EPS
-$5.05
Beta
2.37
Shares outstanding
51.42M
No. of employees
900
News stories
From web sources and news partners
kalkine.ca
·
2 weeks ago
Why Are Emergent BioSolutions (NYSE:EBS) Shares Falling After a 52% Revenue Decline?
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Websiteemergentbiosolutions.com